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Abstract
Background: Many patients with diabetes have poor blood pressure (BP) control. Pharmacological therapy is the
cornerstone of effective BP treatment, yet there are high rates both of poor medication adherence and failure to
intensify medications. Successful medication management requires an effective partnership between providers who
initiate and increase doses of effective medications and patients who adhere to the regimen.
Methods: In this cluster-randomized controlled effectiveness study, primary care teams within sites were
randomized to a program led by a clinical pharmacist trained in motivational interviewing-based behavioral
counseling approaches and authorized to make BP medication changes or to usual care. This study involved the
collection of data during a 14-month intervention period in three Department of Veterans Affairs facilities and two
Kaiser Permanente Northern California facilities. The clinical pharmacist was supported by clinical information
systems that enabled proactive identification of, and outreach to, eligible patients identified on the basis of poor
BP control and either medication refill gaps or lack of recent medication intensification. The primary outcome is
the relative change in systolic blood pressure (SBP) measurements over time. Secondary outcomes are changes in
Hemoglobin A1c, low-density lipoprotein cholesterol (LDL), medication adherence determined from pharmacy refill
data, and medication intensification rates.
Discussion: Integration of the three intervention elements - proactive identification, adherence counseling and
medication intensification - is essential to achieve optimal levels of control for high-risk patients. Testing the
effectiveness of this intervention at the team level allows us to study the program as it would typically be
implemented within a clinic setting, including how it integrates with other elements of care.
Trial Registration: The ClinicalTrials.gov registration number is NCT00495794.
Background
Good glycemic, blood pressure (BP), and lipid control
are central intermediate outcomes of high quality dia-
betes care. Many patients with diabetes, however, have
poor BP, lipid and glycemic control, with particularly
high rates of poor BP [1,2]. Pharmacological therapy is
the cornerstone of effective treatment among hyperten-
sive patients with diabetes [3]. Successful medication
management requires an effective partnership between
providers who initiate and increase doses of effective
medications and patients who adhere to the regimen.
Yet, as Figure 1 shows, multiple factors influence
patients’ and providers’ medication decisions and subse-
quent control of risk factors.
In the face of the complexity of these influences, there
are high rates of both poor medication adherence on
the part of patients and failure to intensify medications
on the part of providers. Poor medication adherence is
associated with disease progression, avoidable hospitali-
zations, premature disability, and death [4]. As many as
half of treatment failures to control BP are due to poor
patient medication adherence that goes unrecognized by
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the provider [5]. Barriers to adherence, such as side
effects, health literacy, medication costs, and regimen
complexity often are not identified or addressed [6].
Many providers do not have effective ways to identify
patients with poor adherence nor the tools or time to
address any barriers to adherence they might identify.
When patients are taking medications as prescribed yet
continue to have poor risk factor control, primary care
clinicians often do not intensify medication regimens
[7,8]. This “clinical inertia” [9] is associated with poor
control of BP, lipids and glycemia, [7,8] while intensifi-
cation is associated with better control [10].
This body of evidence supports the need for restruc-
turing primary care to develop effective team-based and
case management approaches to improving risk factor
control in chronic disease care [11,12]. Improving
patients’ medication adherence and timely initiation or
intensification of medications can be complex and time-
consuming. Time limitations, competing demands, the
burden of comorbid illness and inadequate mechanisms
for follow-up all constitute barriers to treatment modifi-
cations and adherence support. Perhaps for these rea-
sons, prior interventions that focus exclusively on
physicians, prompting them about abnormal clinical
indicators and providing guidance on treatments or
guidelines during standard clinical visits have shown
minimal effects on clinician behavior and patient out-
comes [13-15].
Interventions tailored to overcome patient-specific
barriers have been found to be the most promising
approaches to enhance patient medication adherence
[16]. Several recent RCTs have shown that nurse case-
managers and clinical pharmacists trained in behavioral
approaches can improve patient adherence to BP medi-
cations and improve patients’ BP control [17-20]. In par-
ticular, there is growing evidence that motivation-based
approaches improve medication adherence. RCTs have
shown that brief Motivational Interviewing (MI) training
for clinicians is effective for improving adherence, espe-
cially if there is some follow-up contact after an initial
training [21,22].
Similarly, growing evidence suggests the importance of
team-based approaches to reduce clinical inertia. A 2005
Agency for Healthcare Research and Quality (AHRQ)-
sponsored systematic review of 63 BP quality improve-
ment (QI) interventions concluded that interventions
that assigned non-physician staff to address BP manage-
ment had the largest effects on outcomes [15]. As the
AHRQ report concluded, however, while these efficacy
trials are promising, “the most striking finding from
these systematic reviews is the need for additional, high
quality research to clarify how best to translate research
into practice.”[15]
Despite recognition that poor adherence leads to
worse outcomes, most health care providers currently
must rely on patient self-reporting and/or their own
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Figure 1 Factors influencing providers’ medication prescribing and patients’ adherence to medications.
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suspicions to identify adherence problems. Yet, physi-
cians’ estimates of patient adherence correlate poorly
with objectively measured medication adherence [23]. A
critical first step to improving adherence is to be able to
identify patients with poor adherence and target inter-
ventions to assist these patients. The method used to
estimate adherence must be simple and sensitive to var-
iations in adherence that meaningfully affect health out-
comes. Most indirect (e.g., patient report, physician
estimate, pill count, electronic monitors) and direct (e.g.,
drug level or tracer, direct observation) monitoring
methods have problems with reliability, validity, avail-
ability, cost, or ease of use [24]. In contrast, many health
care systems are moving toward comprehensive electro-
nic data systems that include pharmacy, clinical, and
visit data. Such data systems currently are available in
health systems such as Kaiser Permanente (KP) and the
Department of Veterans Affairs (VA) and provide an
unobtrusive, objective, and readily available source of
adherence information [25,26]. The use of such data in
routine clinical practice to flag and enable proactive tar-
geting of patients with significant medication refill gaps
has been found to be both feasible and sustainable and
to have significantly greater sensitivity than self-report
adherence [27-29]. These results suggest that refill data-
based adherence measurements may be useful measures
to improve both adherence and relevant clinical
outcomes.
Integrated information systems also provide new
opportunities to evaluate whether appropriate treatment
intensification has occurred in response to elevated risk
factor values. Medication intensification measures in
response to poor lipid control constructed from auto-
mated data agree highly with those constructed from
medical record review [30]. Thus, electronic data can
also be used to monitor providers’ intensification of
medications and thereby inform interventions to address
clinical inertia. Preliminary evidence suggests, however,
that simply providing adherence and treatment intensifi-
cation information to physicians does not improve
either adherence rates or reduce clinical inertia [31].
The evidence suggests that use of electronic data to
identify adherence and treatment intensification defi-
ciencies will be most effective if incorporated into a
team-based approach enabling that information to be
acted on and followed up through use of evidence-based
behavioral approaches, standardized treatment algo-
rithms and collaboration across providers.
Accordingly, a system-level intervention to improve
BP and other risk factor control among diabetes patients
must address several elements. First, mechanisms are
necessary to identify and proactively target patients with
poor risk factor control who are not taking medications
as prescribed or requiring medication intensification.
The use by many health systems of electronic pharmacy
prescribing systems with links to refills and patient bio-
medical data presents new opportunities to systemati-
cally monitor both patients’ medications adherence and
providers’ patterns of medication intensification. Second,
an intervention must address sequentially the complex-
ity of both adherence and intensification, because adher-
ence must be addressed before intensification is
initiated. This requires a provider trained in both effec-
tive behavioral approaches and in pharmacological man-
agement. Third, there needs to be follow-up once a
behavioral or pharmacological change has been initiated.
This requires care organization providing contacts at
appropriate intervals with appropriate providers.
Addressing complex medication management issues
while taking account of potential medication interac-
tions and minimizing side effects in these complex
patients is a difficult task well suited to the skills of a
clinical pharmacist authorized to make medication
changes who has also received additional training in
adherence counseling approaches.
We therefore designed and implemented an effective-
ness intervention that combines approaches separately
shown in RCTs to be effective in improving risk factor
control: tailored adherence counseling and medication
management delivered by a clinical pharmacist. The
clinical pharmacist was supported by clinical informa-
tion systems that identified eligible patients and charac-
terized their recent patterns of medication adherence
and intensification. This proactive approach allows iden-
tification and targeting of patients in need of an inter-
vention whether or not their primary care physicians
have recognized their need for intensification or adher-
ence counseling The effectiveness of this intervention is
being tested in real-world practice settings, randomizing
this tailored pharmacist approach among intervention
and usual care primary care teams within clinic sites
in two health systems: two clinical sites within KP
Northern California and three VA health care facilities
in the Midwest. We posit that integration of proactive
identification, adherence counseling and medication
intensification is essential to achieve optimal levels of
control for high-risk patients. Testing the effectiveness
of this intervention at the team level allows us to study
the program as it would typically be implemented within
a clinic setting, including how it integrates with other
elements of care. If shown to be effective, this design
will allow a more seamless future translation to other
practice settings.
Methods
Experimental Design Overview and Aims
This study was conducted as a cluster-randomized effec-
tiveness study in which primary care teams, within sites,
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were randomized to one of two conditions: proactive
case identification followed by adherence counseling and
medication management delivered by a clinical pharma-
cist trained in behavioral counseling approaches (moti-
vational interviewing) or usual care. This study involves
the collection and analysis of both quantitative and qua-
litative data (the latter primarily at VA sites) during a 14
month intervention period. Qualitative data were also
collected at VA sites before the intervention to assess
how to make the intervention most effective and after
the intervention to evaluate the implementation process,
attainment, and sustainability.
Randomization occurred at the team level to evaluate
the real-world effectiveness of pharmacist-team interac-
tions rather than just the efficacy of pharmacist interac-
tions with selected patients and to minimize cross-over
contamination. At three of the study sites, existing pri-
mary care teams were randomly assigned to two inter-
vention teams and two usual care (control) teams. At
the fourth study site, the existing primary care teams
were randomized to one intervention and one usual
care team. At the fifth site, where a true team structure
didn’t exist, two artificial teams were constructed and
randomized to one intervention and one usual care
team, for a total of 8 intervention and 8 control teams.
Each team consisted of primary care providers, their
staff, and patients. All sites were recruited before rando-
mization and then block randomized by site in order to
minimize differences in baseline characteristics due to
site. Randomization was done by random number gen-
erator. Thus allocation concealment was achieved at the
cluster level.
Electronic pharmacy and clinical data were drawn at
quarterly intervals to proactively identify all diabetes
patients within randomly selected primary care teams
who had poor BP control and either poor refill adher-
ence or insufficient medication intensification. Adher-
ence and treatment intensification patterns were also
assessed for glycemia and lipids if either of these was
poorly controlled. Clinical pharmacists were trained in
motivational interviewing (MI)-based counseling
approaches, guided in exploring barriers to taking medi-
cations and development of short-term action plans
with patients[32,33] by an information technology (IT)
application, and authorized to adjust BP and lipid medi-
cations following site-approved treatment algorithms.
Patients in the non-intervention teams received usual
care enhanced by information given to providers about
patients’ adherence and intensification problems.
The Specific Aims of this multi-site, cluster rando-
mized, controlled trial are:
1. To evaluate the effects of the intervention on BP,
glycemic, and lipid control;
2. To assess the impact of the intervention on
patients’ adherence to BP, anti-hyperglycemic, and
lipid-lowering regimens, and intensity of these
regimens;
3. To evaluate the cost-effectiveness of the interven-
tion compared to usual care;
4. To evaluate the process of intervention implemen-
tation in Kaiser and VA sites and identify similarities
and differences across sites that may relate to inter-
vention generalizability.
Conceptual Framework Guiding Intervention
The pathways by which we hypothesize our intervention
elements will affect outcomes are illustrated in Figure 2.
A key theory underpinning our intervention is Self
Determination Theory (SDT)[34-36] a theory that sug-
gests that effective interventions need to encourage
patients to articulate their own values and goals (auton-
omy), be convinced that recommended behaviors corre-
spond with these intrinsic values and goals (autonomous
motivation), and have confidence in their ability to
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execute the targeted behaviors (competence). Another
congruent behavioral theory informing our intervention
is social cognitive theory (SCT) [37,38]. SCT also builds
on the importance of understanding the personal sal-
ience of a health risk and of developing intrinsic motiva-
tion to change behaviors. It further emphasizes the
importance of patients’ confidence (or self-efficacy) in
their ability to execute specific tasks. Self-efficacy has
been shown to improve physiologic outcomes and func-
tioning,[39] and SCT theory has underpinned many of
the most successful chronic disease self-management
support programs evaluated to date [40,41]. The clinical
pharmacists were thus trained in Motivational Inter-
viewing (MI)-based approaches that emphasize the
fostering of patients’ autonomous motivation and self-
efficacy to execute successfully their diabetes medication
and other self-care tasks.
Settings
This intervention took place within the outpatient pri-
mary care clinics at three VA facilities and two KP facil-
ities. The VA facilities were two large academically
affiliated medical centers and one large community-
based outpatient clinic. The KP facilities were two large
medical centers. The study protocol was approved by
the following local Institutional Review Boards [IRBs]:
1. Ann Arbor VAMC Subcommittee on Human Studies;
2. Wayne State University Human Investigation Com-
mittee; 3) Kaiser Permanente Northern California IRB.
Because the clinical pharmacist program was treated as
a standard quality improvement clinical program,
patients were not required to provide consent to partici-
pate in the intervention. However, VA patients partici-
pating in the intervention were required to provide
consent to allow their program data, defined as data
collected by the pharmacist in the IT application, the
Medication Management Tool (MMT) described below,
to be used for the evaluation of the intervention and, if
selected, to participate in an interview to discuss their
experiences with the program.
Pharmacists
Five clinical pharmacists, three in KP and two in VA,
participated in the intervention. Two of the pharmacists
in KP worked part-time for the AIM program, for a
total of 2 FTE assigned in KP and 2 FTE assigned in
VA. All pharmacists participated in a 3-day, interactive
training prior to delivering the intervention. The focus
during two days was on motivational interviewing (MI)
based approaches to behavior change counseling. Speci-
fics of the study protocol and procedures and instruc-
tion on the use of the MMT completed the training.
The MI behavior change training was led by a MI expert
from Kaiser Permanente’s Regional Health Education.
All pharmacists remained with the program throughout
the intervention period.
Medication Management Tool (MMT)
A key tool used in the intervention was the Medication
Management Tool, a database developed by the study
team to assist the pharmacist in tracking and schedul-
ing patient contacts and encounters, assessing medica-
tion adherence, providing adherence counseling,
making short-term action plans with patients, and col-
lecting data. Key components of the MMT included a
summary of refill gap information (e.g., % gap in past
year, gap days before each fill) for each blood pressure,
blood sugar, and lipid medication prescribed at the
time of eligibility, a detailed listing of these medica-
tions, daily doses, questions to document pharmacist
assessment of medication adherence and reasons for
non-adherence to these medications, if applicable. The
MMT also included sections for: 1) recording BPs
taken at home by the patient and clinical blood pres-
sures taken by the pharmacist (KP and VA) or medical
assistants (KP only); 2) documenting patient’s goals
and values and how medications support or interfere
with their goals and values; 3) assessing a patient’s
readiness to change, exploring ambivalence (if appro-
priate), and eliciting the patient’s action plan or next
steps, including barriers and solutions to the plan or
steps; 4) documenting whether medications were chan-
ged during the visit because of adherence issues or
other issues; and 5) if appropriate, recording the rea-
son the patient was discharged from the intervention.
See Figure 3 for the first MMT screen pharmacists saw
at the beginning of the first encounter with an indivi-
dual patient.
Patients
Inclusion criteria
Using automated clinical data, patients were identified
as having diabetes if, within the previous 12 months,
they had: (1) one hospitalization or two outpatient visits
with a diabetes related ICD-9 code of 250.xx, 357.2,
362.0, or 366.41; or (2) at least one prescription for a
diabetes medication (excluding glucose monitoring sup-
plies). To be eligible for the study diabetic patients
needed to have persistent poor blood pressure (BP) con-
trol, defined as: (1) Most recent systolic blood pressure
(measured in last 3 months and the lowest of the day) >
= 140 AND a mean systolic BP in the last 9 months > =
140; or (2) Most recent systolic blood pressure (mea-
sured in last 3 months) > = 150 AND no other BP mea-
sures in last 9 months. Blood pressures obtained from
the following clinics were excluded: ER, urgent care,
hospital medicine (KP), inpatient, and all surgery
departments.
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In addition to meeting BP criteria, patients had to
have poor refill adherence or insufficient medication
intensification. Poor refill adherence was defined as refill
gaps totaling > = 20% of days supply of at least one BP
medication over the prior 12 months after taking into
account stockpiling and hospitalizations. Patients were
identified as having insufficient medication intensifica-
tion if none of the following occurred within 30 days
prior to or any time after the last blood pressure: 1)
increase in the number of prescribed drug classes; 2)
increase in daily dosage of an ongoing medication; 3)
switch to another medication from the same class or to
another medication from a distinct class.
Exclusion criteria
Patients were excluded if automated data indicated any
of the following: impaired decision making (i.e., demen-
tia, traumatic brain injury), pregnancy, or age younger
than 18 or older than 100. Patients in KP were also
excluded if, at the time of the data pull, they were part
of KP’s ‘no contact list’; hospitalized; a resident of a nur-
sing facility; receiving hospice or home health care; or
had less than 12 months of an active drug benefit in the
past year.
Usual Care
Patients assigned to the usual care groups received stan-
dard health care services through their primary care
provider. Additionally, at VA sites, providers on usual
care teams received reports on each of their diabetic
patients who had poor blood pressure control and
adherence or intensification issues. The information
used to produce the report was available in the medical
record, although not in the format provided. No recom-
mendation was given regarding follow-up for patients
Figure 3 Medication Management Tool [Initial Screen].
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listed on the report. At KP sites, these reports were not
required. Instead, in KP, patients in usual care may have
been contacted by clinical pharmacists as part of KP’s
PHASE (Preventing Heart Attacks and Strokes Every-
day) program to outreach to patients at high risk for
cardiovascular disease (CVD) events. However, pharma-
cists working with PHASE receive no training in MI,
and do not have access to the MMT or any other IT
tools that provide adherence or intensification data. In
addition, the PHASE program focuses on brief contacts
with patients, as opposed to longer episodes of care to
address CVD risk factor values.
Intervention
The intervention period was defined as the 14 months
in which eligible patients were being identified and
offered encounters with the pharmacists. Enrollment of
patients occurred during months 1-14. Eligibility for the
intervention was determined at the beginning of the 14-
month intervention period and again at 3, 6, 9, and 12
months. At the start of each quarter, pharmacists
received a list of patients with poor blood pressure con-
trol and adherence problems or inadequate medication
intensification. The list was randomized within 3 blood
pressure strata (> = 160, 150-159, 140-149) to allow out-
reach to the patients with higher blood pressure levels
first. The data were then loaded into the tool used by
the pharmacists (MMT) described above. Pharmacists
were instructed to contact patients in the order that
they appeared on their list. At the end of each quarter,
if no attempts had yet been made to contact a patient
(i.e., the size of the pharmacist’s current patient panel
was such that the pharmacist did not have time to con-
tact that individual as well as individuals further down
the list), that patient was removed from the pharmacist’s
list.
Prior to being contacted by the pharmacist, patients at
the VA sites were notified via a letter mailed by the
study team that a pharmacist would be contacting them
to invite them to participate in a new clinical program,
a customary VA practice for new projects and programs,
and therefore required by the governing IRBs. This let-
ter was not required by the IRB governing the KP sites
because patients in KP are accustomed to being con-
tacted by the health plan for clinical outreach.
Initial contact by the pharmacist
After a brief review of the patient’s electronic medical
record (EMR) and information supplied in the MMT,
the pharmacist attempted to contact the patient. Often
multiple attempts (e.g., leaving messages, calling back at
a more appropriate time) were required before talking
to a patient. After describing details of the program, the
pharmacist invited the patient to participate. If a patient
indicated interest in participating, a phone or in person
intake encounter was scheduled. Additionally, after a
patient agreed to participate in the intervention, the
pharmacist mailed a welcome packet to the patient. The
packet included an introduction letter from the pharma-
cist and educational materials, including instructions for
home monitoring and documents to record blood pres-
sures and action plans. Information on the patient’s cur-
rent medications was occasionally also included in the
packet.
After five attempts to reach a patient without making
any contact whatsoever, the patient was considered
unreachable and a note was placed in the EMR stating
that the patient was eligible for the program but could
not be reached to assess interest in the program. If a
patient was reached but declined to participate, a few
questions were asked to ascertain the reason(s) for
declining and to obtain basic sociodemographic infor-
mation. Pharmacists also notified providers, via a note
in the electronic medical record, when a patient
declined to participate in the program.
Encounters with the pharmacist
Encounters took place in clinic settings or by phone. A
patient who had access to a home blood pressure cuff
and was willing and able to monitor at home could
choose to have encounters via phone, otherwise encoun-
ters occurred in the clinic. Blood pressure monitors
were a covered benefit at VA sites and pharmacists
facilitated obtaining one for VA patients who did not
already have one. At KP, if patients did not have a
home monitor, information was provided about how to
obtain and use one.
Pharmacists were provided with an outline (or ‘road
map’) during the training session as a guide for structur-
ing the flow of an intake encounter and as a tool to
reinforce motivational interviewing principles and tech-
niques. [See Additional file 1.] The roadmap was
reviewed regularly at biweekly conference calls or webi-
nars among all participating pharmacists and study staff
during the early part of the intervention when pharma-
cists were becoming familiar with this behavioral coun-
seling approach and the study protocol. As expected, as
the study progressed each pharmacist modified the
roadmap slightly (e.g., changed wording of example
questions) to follow their own personal style.
During each encounter, the pharmacist worked on
developing rapport with the patient and establishing an
environment of collaboration, mutual respect, and trust.
Additionally, following the MI approach, pharmacists
strived to be nonjudgmental, empathetic, and encoura-
ging. Adherence was assessed at every encounter by
using a standard adherence question (In the last week,
how many days did you miss one or more doses of your
medication?) and at the intake encounter by assessing
adherence for each prescribed hypertension, lipid, and
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dm medication (e.g., Can you tell me how you are taking
your atenolol?). Barriers to taking these medications
were explored as well. After assessing adherence, recent
clinical indicators (blood pressure, A1c, and LDL) were
discussed. This discussion included a comparison of the
patient’s recent numbers with their target numbers. If
the encounter was in-person, a blood pressure was mea-
sured by the pharmacist (or medical assistant (MA) at
KP) as per standard JNC-7 protocols [3]. Labs were
ordered according to the treatment algorithms.
Following the assessment and discussion of clinical
indicators, the pharmacist elicited the patient’s goals and
values and talked with the patient about how taking
medications might interfere and support those goals and
values. Then, based on the information available, the
pharmacist evaluated whether the patient had any
adherence issues. If not, and poor control persisted, the
pharmacist explored with the patient the option of med-
ication change as a means to better control blood pres-
sure. Hypertension medication changes were made
using locally approved medication algorithms. Conver-
sely, if the information gathered suggested that adher-
ence issue(s) still persisted, the pharmacist elicited the
patient’s idea(s) for improving medication adherence.
The patient identified a general target behavior (e.g.,
remember to take medications, increase exercise) and
then ambivalence was explored, by considering the pros
and cons of the behavior change, with the patient. Facil-
itating patient’s full exploration of both sides of the
behavior enhances the patient’s understanding, motiva-
tion, and importance of the target behavior. The
patient’s readiness to change was then assessed using a
readiness ruler (with 0 indicating the patient is not at all
ready to make the change and 10 indicating the patient
is completely ready to make the change). If appropriate
(i.e., patient’s readiness score > = 7), a specific, short-
term action plan was constructed by the patient (e.g.,
pick up new blood pressure medication at pharmacy on
Tuesday and take it three times a day with meals; moni-
tor blood pressure 2 times each day [once in AM and
once in PM]; walk on the treadmill 30 minutes on Mon-
day, Wednesday, and Friday mornings). Possible barriers
to completing the action plan and solutions to overcome
any barriers were then discussed. If a patient was not
ready to make a behavior change, a next step was con-
sidered (e.g., think about adding a blood pressure medi-
cation and discuss at next encounter if blood pressure
remains high). At the end of the encounter, the pharma-
cist summarized the action plan or next step and sched-
uled a follow-up encounter. Follow-up appointments
were to be scheduled weekly if adherence issues were
being addressed and every three weeks if medication
changes were being made. In practice, patients and
pharmacists negotiated appointments based on these
factors and convenience to the patient. All encounters
were documented in the EMR. Follow-up encounters
focused primarily on assessing medication adherence
(including barriers to adherence), review of progress on
prior action plans, additional action planning, and, when
appropriate, intensification of medications.
Discharge Criteria
A patient was eligible for discharge from the program
when the following criteria were met:
1. Medication adherence issues addressed
2. Home BP or clinic BP, measured by pharmacist or
MA, at target [defined for VA patients as average
<135/80 and for KP patients as average <130/80 -
based on VA vs. KP blood pressure guidelines]; or a
diastolic blood pressure <60; or on maximum blood
pressure medications
3. On at least a moderate dose statin, if a candidate
for statin therapy
4. Glycemic control addressed (KP pharmacists made
initial adjustments to hypoglycemic medications if
A1c was above target and adherence was appropri-
ate, then referred back to PCP; VA pharmacists
referred to PCP or case manager for glycemic medi-
cation management after adherence issues were
addressed)
Additionally, patients were discharged from the pro-
gram if they were lost to follow-up (e.g., no showed for
three scheduled encounters), enrolled for 6 months
without achieving blood pressure target (and no pro-
gress in any area was being made), or declined further
participation. Providers were notified via a note in the
electronic medical record when a patient was discharged
from the program as well as when a patient initially
enrolled and when medication changes were being
made.
Reentry
Patients who had been previously discharged but who
met the eligibility criteria (i.e., poor BP control with
adherence gaps and/or insufficient medication intensifi-
cation) in subsequent quarters were allowed to reenter
the program for additional adherence and/or intensifica-
tion assistance; however, a three month window was
required before reentry (e.g., patients discharged in the
second quarter of the intervention period and eligible
again in quarter 3 could not reenter in quarter 3 but, if
still eligible in quarter 4, could reenter then).
Intervention Fidelity
As mentioned above, each pharmacist participated in an
intensive motivational interviewing training course prior
to delivering the intervention to eligible patients. During
the intervention period, fidelity was assessed and MI
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strategies and techniques were reinforced during
biweekly webinars, two self-evaluations (completed at
month 6 and month 11), and a one-on-one booster ses-
sion. The booster session occurred approximately six
months after the intervention started and consisted of
an expert in motivational interviewing observing one or
two phone encounters of each pharmacist and providing
immediate feedback. A rating form, modified from
Resnicow’s 1-Pass Coding System for MI[42] was devel-
oped for use during the one-on-one observations.
Data Sources
Data from the following sources will be included in ana-
lyses: Automated data systems, MMT, and survey (base-
line and follow-up). Additionally, data sources for the
implementation evaluation include: patient interview
data (VA), key informant interview data (VA; pharmacy
managers only in KP), and pharmacist interviews (KP;
VA) and observations (VA).
Outcome Measures
Primary Outcome
The primary outcome is the relative change in systolic
blood pressure measurements over time as recorded at
the point of care in VA and KP electronic databases
(excluding blood pressures measured by the AIM phar-
macists). As this is an effectiveness study, change in
each group will be assessed by the comparison of a pre-
cision weighted average of the values obtained during
routine outpatient clinical practice in 6 month windows
preceding and following the intervention period. The 6
month windows placed on either side of the interven-
tion period ensure that a positive finding of the study
would suggest a persistent effect on BP and not just a
transient effect during the intervention. Secondary out-
comes are described in Table 1.
Design Issues for analysis and sample size calculations
There are several important decisions we had to make
in the design of the study that affect the analysis and
sample size calculations for this study. The most impor-
tant was whether our primary analysis was focused on
the effectiveness or efficacy of the intervention. As
noted above, pharmacist interventions have been shown
to improve blood pressure in a variety of experiments
that focused on randomly sampled individuals treated
by research staff and who gave informed consent for the
intervention prior to inclusion in the study. These are
best characterized as trials of efficacy of the
intervention.
Our study is intended to measure the ability to trans-
late these findings into practice by deploying the inter-
vention to clinic sites using staff and training that
already exist or could easily be integrated into those
settings and evaluating the impact on the entire popula-
tion including those who ultimately decide not to accept
the intervention. Thus, corresponding to an intention to
treat analysis, all contacted patients, regardless of
whether they were successfully contacted and enrolled
in the intervention, will be included in the primary ana-
lyses. Patients will be analyzed within the group (inter-
vention or control) they were assigned to at the time
they first became eligible for the intervention. In this
way the comparability of the patients in the intervention
and control groups is maintained.
Another impact of this orientation on our design was
that the perspective we took in our principal evaluation
was that of the health center director, trying to decide
whether to invest the resources to implement this inter-
vention. In terms of the analysis plan, this meant that
our principal analysis was whether teams that were ran-
domized to the AIM intervention had a larger sustained
decline in blood pressure among patients eligible for the
intervention than teams that were randomized to the
control intervention. We felt the most compelling argu-
ment could be made if the intervention group had a lar-
ger decline in the average blood pressure as measured
by comparing the 6 months after the intervention year
to the 6 months prior to the start of the intervention.
It was felt to be important to use blood pressures
obtained through routine care to assess the impact of
the intervention, again to maintain comparability to the
control group who would otherwise have to be invited
for special visits to measure their baseline and post-
intervention blood pressures. As the number of mea-
surements may vary and thus provide more or less pre-
cise estimates of the two endpoints, it is not possible to
simply construct a difference between the average pre-
and post BPs. We will use all data when multiple mea-
surements allow us to estimate a change in BP more
precisely as well as those observations in which only 1
measurement occurs in each period with weighting to
reflect the varying precision of the estimates.
A three-level multilevel model will allow us to do this
with the multiple individual BP measurements (both pre
and post intervention) at level 1 nested within patient
identifier at level 2 and team at level 3. An indicator
variable will represent whether the BP is from the pre
or post period coded so that the coefficient estimates
the change in mean BP for the control group. The coef-
ficient of an indicator variable representing treatment
teams will estimate the mean BP difference between
treatment and controls in the baseline period. The pri-
mary hypothesis will be tested by an interaction term
between the treatment group indicator and the time
period indicator variables. The multilevel structure of
the model will account for the varying precision with
which the BP endpoints are estimated and the clustering
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of patients within teams. Site will be included as a fixed
variable.
We want to be able to describe reasons for the
diminution or failure of the intervention to reduce
blood pressure relative to effect sizes seen in the prior
efficacy studies, particularly if those factors are amen-
able to changes in protocol that could ameliorate their
impact. While it is possible that a successful interven-
tion will show persistence of effect into the 6 month
post-intervention window, it is possible that we will
lose some power to detect an effect by sample loss if
patients do not have recorded blood pressures during
that period. Furthermore, some patients will have
received the intervention early in the course of the
intervention period and thus may be as much as 1 year
out from the intervention when the 6 month post-
intervention period ends and would have become eligi-
ble for repeat enrollment and improvement in the
blood pressure if the intervention were an ongoing
program at the site.
Therefore, a secondary analysis will examine the blood
pressure slope starting at the point where patients are
activated (initiation of contact for the intervention).
Blood pressure changes will be looked at as a function
of time after activation. As the activation is determined
by random sampling from the list of eligible cases
(within systolic blood pressure groups), the entire con-
trol group can be used for comparison with their activa-
tion date being randomly assigned during the quarter in
which the controls meeting eligibility criteria are identi-
fied. We will compare the amount of decrease in blood
pressure between the intervention and control groups in
both the first and second 3 month periods following
activation.
A second reason for lack of effect may be that sub-
stantial numbers of patients are not willing to partici-
pate in the intervention. It is important to quantify this
rate of refusal, as well as to try to estimate the effect of
the intervention among compliers so that we can assess
whether our intervention achieved similar benefits to
prior studies among comparable populations of com-
pliers. A naive as-treated analysis is clearly flawed as the
comparability between intervention and control groups
is lost when we only analyze those patients in the inter-
vention who accepted the intervention. Thus we will
carry out a complier average causal effect (CACE) analy-
sis in which the randomization is used as an instrument
to estimate the effect of the intervention among the
complier population in both the intervention and con-
trol group [43].
Analysis for secondary outcomes
In addition to secondary outcomes mentioned in Table 1,
we will conduct a cost-effectiveness analysis to determine
differences in costs and utilization between the interven-
tion group and control group patients including total
medical care costs, costs and utilization by category (e.g.,
pharmacy, inpatient, outpatient). To test for differences
in costs and resource use by treatment and control group
status we will use statistical approaches, as previously
described, that account for the non-independence among
patients receiving care from the same team and within
the same system. In addition, since both counts of
resource utilization and costs are usually quite skewed,
alternative modeling techniques, such as Poisson regres-
sion, negative binomial regression or a generalized
gamma regression will be used as appropriate. Given
the longer-term expected benefits of the intervention in
preventing high cost diabetes-related macro- and
Table 1 Secondary Outcomes
Description Time period Planned analyses
A1c Change in the percentage of eligible patients with an
average A1c > 8%
6 months preceding
and following
intervention period
Hierarchical logistic regression with a dichotomous
dependent variable indicating whether each patient on a
team is in control or not in each of the baseline and post
intervention periods. The cluster identifier is the team, and
the analysis will be stratified by site with fixed site effects.
Using an analogous model, the primary hypothesis will be
tested by examining the interaction between the treatment
group variable and the time period variable at the laboratory
measurement level.
LDL Change in the percentage of eligible patients with an
LDL-c >100 mg/dl
6 months preceding
and following
intervention period
[See A1c]
Medication Adherence Change in rates of poor adherence
(>20% gap days)
12 months preceding
and following
intervention period
Regression with a logit link and binomial error term
Medication Intensification Count of medication intensification
events for BP, lipid, and hypoglycemic therapy
[intensification event defined as 1) an increase in the dose
of at least one medication or 2) the addition of another
medication, or both]
During intervention
period
Negative binomial regression
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microvascular events the primary cost-effectiveness
analysis will be conducted using a Markov simulation
model. This analysis will be conducted from both a
health plan/provider perspective and from a societal per-
spective as recommended by the Consensus Panel on
Cost-Effectiveness Analyses in Health and Medicine.
Sample Size
Our perspective focusing on effectiveness had a substan-
tial impact on our sample size requirements and subse-
quent design decisions. Our pharmacist intervention
was designed to be integrated into existing provider
teams, especially with the need for substantial trust
between the providers and pharmacist in order to allow
the pharmacists to make medication adjustments and
the ability to easily consult with providers should discus-
sion about those adjustments be required. Thus, we
needed to randomize provider teams to intervention vs.
control rather than individuals.
A cluster randomized trial requires substantially larger
sample sizes than a simple RCT, contingent on the
amount of clustering of the dependent variable by team
as measured by the intraclass correlation coefficient
(ICC). We attempted to ameliorate the effect of cluster-
ing in several ways. First, the focus on difference in
blood pressure as opposed to post intervention blood
pressure removes much of the potential systematic
patient differences in blood pressure across teams.
Furthermore, we decided to randomize teams within
site, essentially moving all of the between site variation
in blood pressure decline to a stratification variable that
can be adjusted for in the analysis. Prior work suggests
that ICCs for blood pressure are well under 0.02 for
physician teams, much less than for sites of care
[44-48]. Furthermore, focusing on the change in blood
pressure rather than a cross sectional blood pressure
measurement will reduce this clustering even further.
Our sample size calculations demonstrated that with
an average of 275 participants contacted (or attempted
to be contacted) per team, we could detect a 4.4 mmHg
difference with a power 0.8 with only 2 observed blood
pressures per person in each of pre and post interven-
tion measurement windows, under the most pessimistic
assumptions of an ICC of 0.02.
Discussion
Despite efforts to improve BP control among diabetic
patients, control remains suboptimal. In organized
healthcare delivery systems like KP and VA that have
made strides in chronic disease management, BP control
has been successfully addressed for the majority of dia-
betic patients[49] but a significant minority of high-risk
patients still has poorly controlled BP. Over the past
decade, KP and VA have been among the leaders in
reorganizing care to meet the needs of patients with
chronic conditions. Many intervention studies and pro-
grams initially conducted in these integrated healthcare
systems have been incorporated by other healthcare sys-
tems [50-53]. Further, KP and VA already have the tech-
nology capacity that will be available in many health
systems in coming years. Yet, even in KP and VA, a sig-
nificant proportion (20-25%) of diabetic patients with
inadequate BP control persists. Up to 60% of these
patients have adherence problems[54,55] and approxi-
mately 35%[56] appear to have inadequate intensifica-
tion. These patients are likely to need more intensive
approaches than those already in place within standard
chronic disease management programs. Thus, KP and
VA systems are ideal settings to test this intervention.
By conducting the intervention at both KP and VA sites,
we can examine the intervention’s effectiveness across
parallel, but different organizational structures with dif-
ferent patient populations (the VA population being
older, overwhelmingly male, and with higher comorbid
burden), thus enhancing our findings’ generalizability. If
the intervention is effective, the study would provide
impetus for other systems to invest in and adopt infor-
mation technology and population disease management
programs.
A key facet of the intervention is the harnessing of
clinical data to proactively identify eligible patients. We
and others have demonstrated the feasibility of measur-
ing both medication adherence and intensification for
patients with poor control from electronic data systems
[55,57,58] the efficacy of a pharmacist-based interven-
tion to patients[20,59,60] and the effectiveness of tai-
lored adherence interventions in improving risk factor
control [61,62]. However, there is currently no systema-
tic approach for identifying patients with adherence pro-
blems or those who are in need of medication
intensification. Our intervention develops and uses the
methods for identifying those patients in need of further
attention. Our prior work, and that of others, has also
demonstrated that changing the system of care delivery
is necessary to improve quality of care. Indeed, the Insti-
tute of Medicine has made system change the main
tenet of closing the “quality chasm”, and has called
upon healthcare organizations and researchers to imple-
ment state of-the-art approaches that address the fol-
lowing challenges: redesigning care processes based on
best practices; using information technologies to support
clinical decision making; managing knowledge and skills;
and developing effective teams [58]. This study is
designed to address these challenges by using informa-
tion technology to target high risk patients who need
intervention, integrating clinical pharmacists in team-
based care to support best practices, and providing
those pharmacists with the skills necessary to deliver
effective behavioral counseling and medication change.
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While drawing on established and effective interven-
tions, this is the first study to combine these essential
elements to improve outcomes for patients with
diabetes.
If successful, this intervention will be directly transla-
table to the several million diabetic patients who receive
care in integrated healthcare systems such as the VA
(approximately 1 million diabetic patients), KP (approxi-
mately 650,000 patients), Healthcare Partners, Group
Health, and other large integrated and academic sys-
tems. With the implementation of Medicare Part D,
clinical pharmacists can now be reimbursed for medica-
tion therapy management (MTM) services. Health plans
beyond KP are including pharmacist consultation for
patients with diabetes and other chronic conditions.
Moreover, the spread of MTM services has been
strongly advocated by medical associations, such as the
American Medical Association [63]. Incorporating phar-
macists is also consistent with care organization
approaches advocated by the National Diabetes Educa-
tion Program [64]. The critical next step, however, is to
identify the most effective means of involving pharma-
cists to help manage medications for diabetes patients.
This study leads the way in identifying those means and
can help inform policy decisions about broader pharma-
cist reimbursement. Therefore, the intervention we con-
ducted is both timely and has the potential to be
translatable to the majority of patients with diabetes.
Additional material
Additional file 1: AIM Roadmap. Roadmap for Pharmacists
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